SOURCE: Amazon Biotech, Inc.

June 22, 2006 10:20 ET

Amazon Biotech Phase I/II HIV Clinical Trial Protocol Receives FDA "Green Light"

NEW YORK, NY -- (MARKET WIRE) -- June 22, 2006 --Amazon Biotech, Inc. (OTCBB: AMZBE) (FRANKFURT: B2D) announced today that it has successfully negotiated a phase I/II protocol with the FDA. This allows Amazon Biotech to move forward with implementation of its filed Phase I/II trial of its proprietary AMZ0026 therapy in HIV Positive patients.

The approved protocol is designed to test the safety, immunological and antiviral effects of AMZ0026, Amazon Biotech's anti-HIV parent formula. The double-blind, placebo-controlled clinical trial design involves 32 non-symptomatic HIV subjects who have yet to be treated with Highly Active Anti-Retroviral Therapy (HAART). The six-month study will include the monitoring of T Cell increases and HIV plasma viral load decreases.

Avraham Harris, Director of Clinical Development and Regulatory Compliance at Amazon, explained, "I am excited that we have completed the Protocol design and can move forward with the Phase I/II and complete negotiations of agreements with AIDS study sites."

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical drug company, primarily developing immunomodulator drugs. AMZ0026 is the Company's first such drug to be used for the treatment of HIV/AIDS. The Company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.

Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com.

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof. Commitment to do a study does not represent that the Company has FDA approval on the protocol to start the study.

Contact Information

  • CONTACT:
    LC Group
    Rick Lutz
    (404) 261-1196